Ionis Pharmaceuticals Stock Gross Profit
| IONS Stock | USD 33.34 0.39 1.18% |
Ionis Pharmaceuticals fundamentals help investors to digest information that contributes to Ionis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ionis Stock. The fundamental analysis module provides a way to measure Ionis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ionis Pharmaceuticals stock.
Ionis |
Ionis Pharmaceuticals Company Gross Profit Analysis
Ionis Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Ionis Pharmaceuticals Gross Profit | (207.61 M) |
Most of Ionis Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ionis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Ionis Pharmaceuticals reported (207.61 Million) of gross profit. This is 109.25% lower than that of the Biotechnology sector and 121.84% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.76% higher than that of the company.
Ionis Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ionis Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics of similar companies.Ionis Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Ionis Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.0991 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 4.36 B | ||||
| Shares Outstanding | 158.96 M | ||||
| Shares Owned By Insiders | 0.83 % | ||||
| Shares Owned By Institutions | 99.17 % | ||||
| Number Of Shares Shorted | 12.67 M | ||||
| Price To Earning | 101.16 X | ||||
| Price To Book | 8.90 X | ||||
| Price To Sales | 7.43 X | ||||
| Revenue | 705.14 M | ||||
| Gross Profit | (207.61 M) | ||||
| EBITDA | (475.08 M) | ||||
| Net Income | (453.9 M) | ||||
| Cash And Equivalents | 2.04 B | ||||
| Cash Per Share | 14.36 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 2.00 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (500.95 M) | ||||
| Short Ratio | 7.45 X | ||||
| Earnings Per Share | (3.04) X | ||||
| Price To Earnings To Growth | 25.70 X | ||||
| Target Price | 59.5 | ||||
| Number Of Employees | 1.07 K | ||||
| Beta | 0.28 | ||||
| Market Capitalization | 5.24 B | ||||
| Total Asset | 3 B | ||||
| Retained Earnings | (2.25 B) | ||||
| Working Capital | 2.31 B | ||||
| Current Asset | 837 M | ||||
| Current Liabilities | 148.88 M | ||||
| Net Asset | 3 B |
About Ionis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ionis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.